Brief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
18/05/2026 14:05
May 18 (Reuters) - Provectus Biopharmaceuticals Inc PVCT.PK: PROVECTUS BIOPHARMACEUTICALS REPORTS ORAL PV-10 ANTI-TUMOR ACTIVITY IN PRECLINICAL BLADDER CANCER STUDY; LONG-TERM SURVIVORS SHOW ABSENCE OF GROSS BLADDER TUMOR AT STUDY END PROVECTUS BIOPHARMACEUTICALS INC - INTRAVESICAL PV-10 AT 3 MG/DOSE NOT TOLERATED DUE TO ACUTE MUCOSAL TOXICITY Source text: ID:nGNX6k8cwl Further company coverage: PVCT.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting